218 related articles for article (PubMed ID: 31500891)
1. Posttreatment squamous cell carcinoma antigen predicts treatment failure in patients with cervical squamous cell carcinoma treated with concurrent chemoradiotherapy.
Wang W; Liu X; Hou X; Lian X; Liu Z; Shen J; Sun S; Yan J; Miao Z; Wang D; Meng Q; Fu J; Zhang F; Qiu J; Hu K
Gynecol Oncol; 2019 Nov; 155(2):224-228. PubMed ID: 31500891
[TBL] [Abstract][Full Text] [Related]
2. The role of squamous cell carcinoma antigen (SCC Ag) in outcome prediction after concurrent chemoradiotherapy and treatment decisions for patients with cervical cancer.
Fu J; Wang W; Wang Y; Liu C; Wang P
Radiat Oncol; 2019 Aug; 14(1):146. PubMed ID: 31416463
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of pretreatment carcinoembryonic antigen after definitive radiotherapy with or without concurrent chemotherapy for squamous cell carcinoma of the uterine cervix.
Huang EY; Hsu HC; Sun LM; Chanchien CC; Lin H; Chen HC; Tseng CW; Ou YC; Chang HY; Fang FM; Huang YJ; Wang CY; Lu HM; Tsai CC; Ma YY; Fu HC; Wang YM; Wang CJ
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1105-13. PubMed ID: 20932670
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment carcinoembryonic antigen level is a risk factor for para-aortic lymph node recurrence in addition to squamous cell carcinoma antigen following definitive concurrent chemoradiotherapy for squamous cell carcinoma of the uterine cervix.
Huang EY; Huang YJ; Chanchien CC; Lin H; Wang CJ; Sun LM; Tseng CW; Tsai CC; Ou YC; Fu HC; Chen HC; Hsu HC; Wang CY
Radiat Oncol; 2012 Jan; 7():13. PubMed ID: 22289572
[TBL] [Abstract][Full Text] [Related]
5. Can serial evaluation of serum SCC-Ag-level predict tumor recurrence and patient survival in squamous-cell carcinoma of uterine cervix treated with definitive chemoradiotherapy? A multi-institutional analysis.
Choi KH; Yu M; Jeong S; Lee JH
Int J Clin Oncol; 2020 Jul; 25(7):1405-1411. PubMed ID: 32221801
[TBL] [Abstract][Full Text] [Related]
6. Significance of elevated SCC-Ag level on tumor recurrence and patient survival in patients with squamous-cell carcinoma of uterine cervix following definitive chemoradiotherapy: a multi-institutional analysis.
Choi KH; Lee SW; Yu M; Jeong S; Lee JW; Lee JH
J Gynecol Oncol; 2019 Jan; 30(1):e1. PubMed ID: 30479085
[TBL] [Abstract][Full Text] [Related]
7. The predictive value of serum squamous cell carcinoma antigen in patients with cervical cancer who receive neoadjuvant chemotherapy followed by radical surgery: a single-institute study.
Li X; Zhou J; Huang K; Tang F; Zhou H; Wang S; Jia Y; Sun H; Ma D; Li S
PLoS One; 2015; 10(4):e0122361. PubMed ID: 25860888
[TBL] [Abstract][Full Text] [Related]
8. Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma of cervix after definitive radiotherapy or concurrent chemoradiotherapy.
Hu K; Wang W; Liu X; Meng Q; Zhang F
Radiat Oncol; 2018 Dec; 13(1):249. PubMed ID: 30558636
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment Squamous Cell Carcinoma Antigen (SCC-Ag) as a Predictive Factor for the Use of Consolidation Chemotherapy in Cervical Cancer Patients After Postoperative Extended-Field Concurrent Chemoradiotherapy.
Zhang G; Miao L; Wu H; Zhang Y; Fu C
Technol Cancer Res Treat; 2021; 20():15330338211044626. PubMed ID: 34605696
[No Abstract] [Full Text] [Related]
10. Prognostic utility of squamous cell carcinoma antigen in carcinoma of the cervix: association with pre- and posttreatment FDG-PET.
Olsen JR; Dehdashti F; Siegel BA; Zighelboim I; Grigsby PW; Schwarz JK
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):772-7. PubMed ID: 20888130
[TBL] [Abstract][Full Text] [Related]
11. [Outcomes and prognostic factors of distant metastasis in patients with advanced cervical squamous cell carcinoma treated with concurrent chemoradiotherapy].
Ma R; Zhang H; Zou L; Qu Y
Zhonghua Fu Chan Ke Za Zhi; 2015 Feb; 50(2):125-30. PubMed ID: 25877610
[TBL] [Abstract][Full Text] [Related]
12. Preoperative SCC-Ag as a predictive marker for the use of adjuvant chemotherapy in cervical squamous cell carcinoma with intermediate-risk factors.
Guo HT; Bi XH; Lei T; Lv X; Yao G; Chen Y; Liu C
BMC Cancer; 2020 May; 20(1):441. PubMed ID: 32429859
[TBL] [Abstract][Full Text] [Related]
13. Postreatment squamous cell carcinoma antigen as a survival prognostic factor in patients with locally advanced cervical cancer. A Spanish multicenter study. The SEGO Spain-GOG group.
Benito V; Lubrano A; Pérez-Regadera JF; Torné A; Gil-Moreno A; Tejerizo-Garcia Á; Vergés R; Díaz-Feijoo B;
Gynecol Oncol; 2021 Aug; 162(2):407-412. PubMed ID: 34119366
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of preoperative serum squamous cell carcinoma antigen (SCC-Ag) level on tumor recurrence in cervical squamous cell carcinoma patients treated with radical surgery: A single-institution study.
Guo Q; Zhu J; Wu Y; Wen H; Xia L; Wu X; Ju X
Eur J Surg Oncol; 2020 Jan; 46(1):131-138. PubMed ID: 31481274
[TBL] [Abstract][Full Text] [Related]
15. The clinical values of squamous cell carcinoma antigen and carcinoembryonic antigen in patients with cervical cancer treated with concurrent chemoradiotherapy.
Yoon SM; Shin KH; Kim JY; Seo SS; Park SY; Kang S; Cho KH
Int J Gynecol Cancer; 2007; 17(4):872-8. PubMed ID: 17343571
[TBL] [Abstract][Full Text] [Related]
16. The Utility of Pretreatment and Posttreatment Lymphopenia in Cervical Squamous Cell Carcinoma Patients Treated With Definitive Chemoradiotherapy.
Onal C; Yildirim BA; Guler OC; Mertsoylu H
Int J Gynecol Cancer; 2018 Oct; 28(8):1553-1559. PubMed ID: 30247248
[TBL] [Abstract][Full Text] [Related]
17. Maximum Standardized Uptake Value of Pelvic Lymph Nodes in [18F]-Fluorodeoxyglucose Positron Emission Tomography Is a Prognostic Factor for Para-Aortic Lymph Node Recurrence in Pelvic Node-Positive Cervical Cancer Treated With Definitive Chemoradiotherapy.
Kim DH; Kim WT; Bae JS; Ki YK; Park D; Suh DS; Kim KH; Lee JH; Lee JY; Jeon HS; Nam JH
Int J Gynecol Cancer; 2016 Sep; 26(7):1274-80. PubMed ID: 27465890
[TBL] [Abstract][Full Text] [Related]
18. Average log change rate of pretreatment squamous cell carcinoma antigen after concurrent chemoradiotherapy in stage IIIC1 cervical squamous cell carcinoma.
Cho O; Chun M; Chang SJ
Sci Rep; 2024 Apr; 14(1):8710. PubMed ID: 38622276
[TBL] [Abstract][Full Text] [Related]
19. Use of serum squamous cell carcinoma antigen for follow-up monitoring of cervical cancer patients who were treated by concurrent chemoradiotherapy.
Yoon SM; Shin KH; Kim JY; Seo SS; Park SY; Moon SH; Cho KH
Radiat Oncol; 2010 Sep; 5():78. PubMed ID: 20840788
[TBL] [Abstract][Full Text] [Related]
20. Clinical behaviors and outcomes for adenocarcinoma or adenosquamous carcinoma of cervix treated by radical hysterectomy and adjuvant radiotherapy or chemoradiotherapy.
Huang YT; Wang CC; Tsai CS; Lai CH; Chang TC; Chou HH; Lee SP; Hong JH
Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):420-7. PubMed ID: 22365621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
